Sign In
Buy ALNY
$216.98
-2.22 (-1.01%)
At Close: Aug 10, 2026
Pres. Trump's push to lower drug prices 'is a good starting point', says Dr. Scott Gottlieb
08:31am, Friday, 01'st Aug 2025
Former FDA Commissioner Dr. Scott Gottlieb joins 'Squawk Box' to discuss news of President Trump ordering pharma companies to lower U.S. drug prices in the next 60 days, the move to tiered pricing glo
President Trump demands drugmakers slash prices within 60 days
06:54am, Friday, 01'st Aug 2025
CNBC's Joe Kernen reports on the latest news.
Alnylam Pharmaceuticals, Inc. (ALNY) Q2 2025 Earnings Call Transcript
04:47pm, Thursday, 31'st Jul 2025
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY ) Q2 2025 Earnings Conference Call July 31, 2025 8:30 AM ET Company Participants Christine Regan Akinc - Chief Corporate Communications Officer Jeffrey V. Po
Alnylam Pharmaceuticals Q2 Earnings Crush Estimates, Stock Hits 52-Week High On Upbeat Forecast
03:36pm, Thursday, 31'st Jul 2025
The biotechnology sector is witnessing a surge in investor optimism as companies like Alnylam Pharmaceuticals Inc. ALNY continue to outperform market expectations. Amid a backdrop of growing demand fo
Alnylam (ALNY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
11:31am, Thursday, 31'st Jul 2025
The headline numbers for Alnylam (ALNY) give insight into how the company performed in the quarter ended June 2025, but it may be worthwhile to compare some of its key metrics to Wall Street estimates
Alnylam Pharmaceuticals (ALNY) Q2 Earnings and Revenues Beat Estimates
10:17am, Thursday, 31'st Jul 2025
Alnylam Pharmaceuticals (ALNY) came out with quarterly earnings of $0.32 per share, beating the Zacks Consensus Estimate of a loss of $0.03 per share. This compares to earnings of $0.56 per share a ye
Alnylam Pharmaceuticals Reports Second Quarter 2025 Financial Results and Highlights Recent Period Progress
08:00am, Thursday, 31'st Jul 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today reported its consolidated financial results for the second quarter ended J
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release
11:07am, Thursday, 24'th Jul 2025
Alnylam (ALNY) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Alnylam (ALNY) Upgraded to Buy: What Does It Mean for the Stock?
01:01pm, Tuesday, 22'nd Jul 2025
Alnylam (ALNY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Alnylam to Webcast Conference Call Discussing Second Quarter 2025 Financial Results
08:00am, Thursday, 17'th Jul 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter end
Alnylam Pharma Stock Outlook: Is ALNY Topping Out?
09:06am, Tuesday, 01'st Jul 2025
Alnylam Pharmaceuticals ALNY is currently in Phase 10 of its 18-phase Adhishthana Cycle. With this phase scheduled to end in September 2025, the stock remains within its bullish structure.
Alnylam Pharmaceuticals Names Garg R&D Chief
12:04pm, Wednesday, 18'th Jun 2025
Alnylam Pharmaceuticals named Pushkal Garg executive vice president and chief research and development officer.
Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer
10:05am, Wednesday, 18'th Jun 2025
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that Pushkal Garg, M.D., has been appointed E
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM
10:11am, Tuesday, 10'th Jun 2025
ALNY gains approval to expand Amvuttra's label in the EU, boosting its position as the only RNAi therapy for ATTR-CM.
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNA interference (RNAi) therapeutics company, today announced that the European Commission (EC) has granted
